Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
13.69 USD +0.81% Intraday chart for Sage Therapeutics, Inc. +2.70% -36.83%
Apr. 25 Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained MT
Apr. 25 Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
BU
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease
AQ
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
BU
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors
PU
Sage Therapeutics to Present at Upcoming March Investor Conferences
BU
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
BU
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
BU
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
BU
Sage Therapeutics Announces Changes to Board of Directors
BU
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
BU
Sage Therapeutics - ZURZUVAE CIV, a Landmark Oral Treatment for Women with Postpartum Depression, is Now Available in the U.S.
AQ
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
BU
Company Statement: Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor
PU
Sage Therapeutics to Present at Upcoming November Investor Conferences
BU
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
BU
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
BU
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease
AQ
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
BU
Sage Therapeutics to Present at Upcoming September Investor Conferences
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.
  5. Press Releases